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Plasma von Willebrand Factor Levels Are
an Independent Risk Factor for Adverse Events
Including Mortality and Major Bleeding in
Anticoagulated Atrial Fibrillation Patients
Vanessa Rolda´n, MD, PHD,* Francisco Marı´n, MD, PHD,† Begoña Muiña, MD,*
Jose Miguel Torregrosa, MD,* Diana Herna´ndez-Romero, PHD,† Mariano Valdés, MD,†
Vicente Vicente, MD,* Gregory Y. H. Lip, MD‡
Murcia, Spain; and Birmingham, United Kingdom
Objectives The purpose of this study was to evaluate the prognostic value of plasma von Willebrand factor (vWF) levels and
fibrin D-dimer in a large cohort of anticoagulated permanent atrial fibrillation (AF) patients.
Background In nonanticoagulated AF patients, plasma vWF levels have been related to stroke and vascular events. There are
limited data on the prognostic role of biomarkers in anticoagulated AF patients in relation to adverse events (in-
cluding thromboembolism), mortality, and major bleeding.
Methods We studied 829 patients (50% male; median age 76 years) with permanent AF who were stabilized (for at least
6 months) on oral anticoagulation therapy (international normalized ratio: 2.0 to 3.0). Plasma D-dimer and vWF
levels were quantified by enzyme-linked immunosorbent assay. Patients were followed for 2 years, and adverse
events (thrombotic and vascular events, mortality, and major bleeding) were recorded.
Results Patients were followed for a median of 828 days (range 18 to 1,085 days). On multivariate analysis, age 75
years and older, previous stroke, heart failure, and high plasma vWF levels (221 IU/dl) were associated with
future adverse cardiovascular events (all p values 0.05). High plasma vWF levels, elderly patients, diabetes,
hypercholesterolemia, and current smoking were associated with mortality (all p values 0.05). High plasma
vWF levels were also an independent predictor of major bleeding (hazard ratio: 4.47, 95% confidence interval:
1.86 to 10.75; p  0.001). High plasma vWF levels were able to refine clinical risk stratification schema for
stroke (CHADS2 [Congestive heart failure, Hypertension, Age 75, Diabetes mellitus, and prior Stroke or tran-
sient ischemic attack (doubled)], CHA2DS2-VASc [Congestive heart failure, Hypertension, Age 75 years, Diabe-
tes mellitus, Stroke, Vascular disease, Age 65 to 74 years, Sex category]) and bleeding (HAS-BLED [Hyperten-
sion, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile International Normalized
Ratio, Elderly, Drugs/alcohol concomitantly]). D-dimer did not show any significant impact on adverse events.
Conclusions High plasma vWF levels (221 IU/dl) are an independent risk factor for adverse events in anticoagulated per-
manent AF patients. This biomarker may potentially be used to refine stroke and bleeding clinical risk stratifica-
tion in AF. (J Am Coll Cardiol 2011;57:2496–504) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.12.033Atrial fibrillation (AF) is a common cardiac arrhythmia
associated with increased morbidity and mortality. Much of
the AF-associated morbidity is secondary to a 5- to 6-fold
increased risk of stroke (1), but these patients also have a
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June 21, 2011:2496–504 vWF Levels in Atrial FibrillationOral anticoagulation (OAC) is highly effective in reducing
the risk of stroke and thromboembolism. To aid decisions for
thromboprophylaxis, several risk stratification schemes have
been developed using clinical characteristics, the most popular
being the CHADS2 score (1 point for Congestive heart failure,
ypertension, Age 75 years and older, and Diabetes, and 2
oints for previous Stroke) (3). Given the limitations of the
HADS2 score (4), the CHA2DS2-VASc [Congestive heart
failure, Hypertension, Age 75 years, Diabetes mellitus,
Stroke, Vascular disease, Age 65 to 74 years, Sex category]
score has been proposed to complement the CHADS2 score in
ecision making for OAC (5), reflecting a risk factor–based
pproach to thromboprophylaxis (6). In the recent European
ociety of Cardiology guidelines, OAC is recommended in AF
atients at moderate to high risk of stroke and thromboem-
olism (e.g., those with 1 stroke risk factors [6]), whereas in
he 2006 American College of Cardiology/American Heart
ssociation/European Society of Cardiology guidelines, OAC
s recommended with any high-risk factor (previous stroke) or
1 moderate-risk factor (age 75 years and older, hypertension,
iabetes, or heart failure) (7). Whether OAC is useful for the
revention of myocardial infarction and other vascular events
as been debated (8).
von Willebrand factor (vWF) has been proposed as a
iomarker of endothelial damage/dysfunction because in-
reased plasma levels have been found in inflammatory and
therosclerotic vascular diseases in which the endothelium is
ikely to be damaged (9). Fibrin D-dimer (DD) is a fibrin
degradation product and an established marker of fibrin
turnover and thrombogenesis, which has been reported to
be increased in AF as part of the hypercoagulable state in
this arrhythmia (10). Data from the SPAF (Stroke Preven-
tion in Atrial Fibrillation) III study showed an independent
association of plasma vWF level with clinical risk factors for
stroke in AF patients (11) and was shown to be predictive of
subsequent stroke and vascular events in patients who were
treated with aspirin and/or inadequate dosing of warfarin
(12). We also previously showed how plasma vWF levels
correlated with the CHADS2 score (13), and more recently,
inflammatory (14,15) and prothrombotic (16) markers have
been related to prognosis in AF patients, even though they
are receiving OAC therapy. In addition, DD has prognostic
significance in AF, even in patients taking OAC medication
(16–18).
Stroke risk is also closely related to bleeding risk, and
OAC therapy needs to weigh the benefit from stroke
prevention against the bleeding risk. Many thromboembolic
risk factors have also been identified as bleeding risk factors
(e.g., advanced age, uncontrolled hypertension, history of
myocardial infarction or ischemic heart disease, cerebrovas-
cular disease, anemia, a history of bleeding, and the con-
comitant use of other drugs such as antiplatelet drugs) (19).
A simple, novel bleeding risk scoring system (HAS-BLED
[Hypertension, Abnormal renal/liver function, Stroke,
Bleeding history or predisposition, Labile International
Normalized Ratio, Elderly, Drugs/alcohol concomitantly])has recently been proposed as a
practical tool to assess the indi-
vidual bleeding risk of real-world
AF patients (20,21) and has been
incorporated in the European
Society of Cardiology guidelines
(6). However, there is scarce in-
formation on biomarkers for
bleeding risk prediction in AF.
We hypothesized that plasma
vWF and DD levels could be used
to refine clinical risk stratification
for adverse cardiovascular events
(mainly thromboembolism), mor-
tality, and major bleeding in anti-
coagulated AF patients. To test
this hypothesis, we studied the
prognostic value of 2 biomarkers
(vWF and DD) in a large cohort
of AF patients on long-term anti-
coagulation therapy with regard to
adverse events and major bleeding
episodes.
Methods
Patients. We recruited consecu-
tive patients with permanent/
paroxysmal AF from our outpa-
tient anticoagulation clinic who
were stabilized for at least 6 months
with OAC therapy (international
normalized ratio: 2.0 to 3.0). We excluded patients with
valvular AF or prosthetic heart valves, any acute coronary
syndrome, stroke (embolic or ischemic) or hemodynamic
instability in the preceding 6 months, as well as any hospital
admissions or surgical interventions during the same period.
At study entry, we recorded the medical history, and
follow-up was conducted by visits to the anticoagulation
clinic. The CHADS2 and CHADS2-VASc2 stroke risk
cores were recorded as baseline measures of stroke risk
3,5), whereas the HAS-BLED score (20) was calculated as
measure of baseline bleeding risk. The CHADS2 score is
ased on a point system in which 2 points are assigned for
history of stroke or transient ischemic attack and 1 point
s assigned for age 75 years and older, hypertension, diabe-
es, or congestive heart failure. The CHADS2-VASc2
stroke risk score assigned 1 point to congestive heart failure,
hypertension, diabetes, vascular disease, age 65 to 74 years,
and sex category (female) and 2 points for age 75 years and
older and stroke. The HAS-BLED score is the result of
adding 1 point for hypertension, abnormal renal/liver func-
tion (1 point for each one), stroke, bleeding history or
predisposition, unstable international normalized ratio, ad-
vanced age (65 years and older), and drugs/alcohol concom-
Abbreviations
and Acronyms
AF  atrial fibrillation
CHA2DS2-VASc 
Congestive heart failure,
Hypertension, Age >75
years, Diabetes mellitus,
Stroke, Vascular disease,
Age 65 to 74 years, Sex
category
CHADS2  Congestive
heart failure, Hypertension,
Age >75, Diabetes
mellitus, and prior Stroke
or transient ischemic
attack (doubled)
CI  confidence interval
DD  D-dimer
HAS-BLED  Hypertension,
Abnormal renal/liver
function, Stroke, Bleeding
history or predisposition,
Labile International
Normalized Ratio, Elderly,
Drugs/alcohol
concomitantly
HR  hazard ratio
OAC  oral anticoagulation
TTR  time in therapeutic
range
vWF  von Willebrand
factoritantly (1 point for each one).
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vWF Levels in Atrial Fibrillation June 21, 2011:2496–504Adverse cardiovascular endpoints (mainly thromboem-
bolic) were defined as stroke/transient ischemic accident as
well as both embolic and ischemic peripheral embolism,
acute coronary syndrome, and acute heart failure, and
cardiac death. Bleeding events were assessed following 2005
International Society on Thrombosis and Haemostasis cri-
teria, which were recently reviewed (22). Finally, both
all-cause and cardiovascular deaths were recorded.
Blood samples and laboratory analysis. Blood samples
were drawn atraumatically and without stasis into syringes
pre-loaded with trisodium citrate (0.011 mol/l). Platelet-
poor plasma fractions were obtained by centrifugation at
4°C for 20 min at 2,200 g. Aliquots were stored at 80°C
to allow batch analysis. Both plasma vWF and DD levels
were assessed in an automated coagulometer ACL Top 3 G,
HemosIL von Willebrand factor and Hemosil D-Dimer
HS (Instrumentation Laboratory, Lexington, Massachu-
setts). The interassay and intra-assay coefficients of variation
were 1.4% and 9%, respectively, and the lower limits of
detection were 2.2 IU/dl and 21 ng/ml, respectively.
Statistical analysis. Continuous variables were tested for
normal distribution by the Kolmogorov-Smirnov test. Con-
tinuous variables are presented as a mean  SD or median
interquartile range), as appropriate, and categorical vari-
bles as a percentage. We used Cox models to determine the
ssociation of plasma DD and vWF levels with time to
dverse events independently to clinical risk factors.
eceiver-operator characteristic curve analyses were gener-
ted to test the predictive discrimination of both biomarkers
o identify association with adverse events during follow-up.
he cut point with the best sensitivity and specificity was
hosen for each biomarker, as assessed by receiver-operator
haracteristic curves (23). The independent effect of vari-
bles on prognosis was calculated using a Cox proportional
azards regression model, incorporating in the multivariate
odel only those values that showed a p value 0.15 in the
nivariate analysis. A p value 0.05 was accepted as
tatistically significant. Statistical analysis was performed
sing SPSS version 15.0 for Windows (SPSS, Inc., Chi-
ago, Illinois).
esults
e studied 829 patients (50% male; median age 76 years
interquartile range: 70 to 80 years) with clinical character-
stics summarized in Table 1. The median CHADS2 risk
core was 2 (interquartile range: 2 to 3), and 76% of patients
ad a CHADS2 risk score of 2. The median CHADS2-
VASc2 score was 4 (range 3 to 5), and 94% had a
CHA2DS2-VASc score of 2. The median HAS-BLED
core was 2 (range 2 to 3), and 32% of patients had a
AS-BLED score of 3. The median values of vWF and
D were 171 IU/dl (range 131 to 230 IU/dl) and 257 IU/dl
range 177 to 389 ng/ml), respectively.
The median follow-up was 828 days (range 18 to 1,085ays). During this period, 95 patients experienced an 2dverse cardiovascular event (rate: 5.0% per year): there were
2 stroke/transient ischemic attack events (rate: 1.7% per
ear), 36 acute coronary syndrome events (rate: 1.9% per
ear), and 27 acute heart failure events (rate: 1.5% per year)
Table 2). Sixty-nine patients died during follow-up (rate:
.7% per year); the deaths in 25 of the patients were
ardiovascular (rate: 1.13% per year) (Tables 3 and 4).
here were 68 major bleeding episodes (rate: 3.6% per
ear) (Table 5).
nivariate and multivariate analyses. For each adverse
vent (e.g., adverse cardiovascular event, death, and bleed-
ng), we constructed receiver-operator characteristic curves
hat gave a median cutoff point of 221 IU/dl for plasma
WF levels (area under the curve: 0.74; p  0.001; sensi-
ivity 0.73; specificity 0.71). We did not find any cutoff
oint for DD (area under the curve: 0.58; p  0.051).
nivariate and multivariate predictors of adverse cardiovas-
ular events are shown in Table 2, for death and cardiovas-
ular death in Tables 3 and 4, and for bleeding in Table 5.
Multivariate Cox regression analysis showed independent
ssociations for age 75 years and older (hazard ratio [HR]:
Baseline Clinical Characteristicsof Atr al Fibrillation Patients (n  829)Table 1 B seline Clinical Characteristicsof Atrial Fibrillation Patients (n  829)
Male 416 (50)
Age, yrs 76 (70–80)
Age 75 yrs 474 (57)
Hypertension 685 (82)
Diabetes mellitus 207 (25)
Heart failure 303 (36.5)
History of stroke or TIA 152 (18)
Coronary artery disease 157 (19)
Hypercholesterolemia 253 (30.5)
Current smoking habit 111 (13)
Previous bleeding episode 71 (9)
CHADS2 score 2 (2–3)
0 40 (5)
1 157 (19)
2 273 (33)
3 223 (27)
4 98 (12)
5 29 (3.5)
6 9 (0.5)
Concomitant treatment
Aspirin 133 (16)
ACE inhibitors/angiotensin-renin blockers 183 (22)
Calcium antagonist 183 (22)
Beta-blockers 241 (29)
Statins 174 (21)
Digoxin 149 (18)
Diuretics 332 (40)
D-dimer, ng/ml 257 (177–389)
vWF, IU/dl 171 (131–230)
Values shown are n (%) or median (interquartile range).
ACE  angiotensin-converting enzyme; CHADS2  Congestive heart failure, Hypertension, Age
75, Diabetes mellitus, and prior Stroke or transient ischemic attack (doubled); TIA  transient
ischemic attack; vWF  von Willebrand factor..00, 95% confidence interval [CI]: 1.23 to 3.24; p 
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June 21, 2011:2496–504 vWF Levels in Atrial Fibrillation0.005), previous stroke (HR: 1.81; 95% CI: 1.14 to 2.87;
p 0.012), history of heart failure (HR: 1.79; 95% CI: 1.18
to 2.72; p  0.006), and high plasma vWF levels (221
IU/dl) (HR: 2.71; 95% CI: 1.78 to 4.13; p  0.001) for
adverse cardiovascular events (Table 2). The association of a
plasma vWF level of 221 IU/dl with any of the single
components of the composite endpoint gave an HR of 5.04
(95% CI: 2.40 to 10.59; p  0.001), for stroke, an HR of
3.42 (95% CI: 1.75 to 6.70; p  0.001) for acute coronary
yndrome, and an HR of 1.97 (95% CI: 0.93 to 4.20; p 
.078) for acute heart failure.
Independent predictors of all-cause mortality were age 75
ears and older (HR: 3.26; 95% CI: 1.71 to 6.19; p 
.001), diabetes (HR: 1.92; 95% CI: 1.17 to 3.15; p 
.010), current smoking habit (HR: 2.76; 95% CI: 1.56 to
.89; p  0.001), hypercholesterolemia (HR: 0.46; 95% CI:
.25 to 0.85; p 0.014), and plasma vWF level221 IU/dl
Cox Analysis for the Composite of CardiovascularEvents (Stroke, Acute Cor nary Syndrome,Acute Hea t Failure)
Table 2
C x Analysis f r he Composite of Cardiovascular
Events (Stroke, Acute Coronary Syndrome,
Acute Heart Failure)
Univariate Analysis
HR (95% CI); p Value
Multivariate Analysis
HR (95% CI); p Value
Age 75 yrs 2.46 (1.54–3.94);0.001 2.00 (1.23–3.24); 0.005
Male 1.10 (0.73–1.63); 0.677
Hypertension 0.93 (0.56–1.56); 0.783
Diabetes 1.53 (1.00––2.34); 0.052 1.44 (0.93–2.22); 0.099
Previous stroke 2.02 (1.29–3.16); 0.002 1.81 (1.14–2.87); 0.012
Heart failure 2.03 (1.36–3.05); 0.001 1.79 (1.18–2.72); 0.006
Coronary artery disease 1.54 (0.97–2.46); 0.066 1.18 (0.73–1.92); 0.497
Renal impairment 1.53 (0.84–2.81); 0.167
Current smoking habit 1.62 (0.97–2.71); 0.066 1.67 (0.98–2.86); 0.060
Hypercholesterolemia 1.10 (0.71–1.69); 0.672
Previous bleeding 1.56 (0.85–2.85); 0.156
vWF 221 IU/dl 3.33 (2.20–5.04);0.001 2.71 (1.78–4.13);0.001
D-dimer 1.00 (1.00–1.00); 0.989
The bold values indicate significant factors.
CI  confidence interval; HR  hazard ratio; vWF  von Willebrand factor.
Cox Regression Analysis for All-Cause MortalityTable 3 Cox Regression Analysis for All-Cause Mortality
Univariate Analysis
HR (95% CI); p Value
Multivariate Analysis
HR (95% CI); p Value
Age 75 yrs 3.68 (1.98–6.86);0.001 3.26 (1.71–6.19);0.001
Male 0.74 (0.45–1.20); 0.220
Hypertension 1.63 (0.78–3.40); 0.196
Diabetes 1.92 (1.17–3.15); 0.009 1.92 (1.17–3.15); 0.010
Previous stroke 1.58 (0.91–2.75); 0.100 1.44 (0.81–2.57); 0.207
Heart failure 1.80 (1.11–2.91); 0.016 1.56 (0.95–2.57); 0.080
Coronary artery disease 1.14 (0.63–2.06); 0.653
Renal impairment 2.04 (1.07–3.90); 0.032 1.28 (0.65–2.53); 0.480
Current smoking habit 2.15 (1.24–3.71); 0.006 2.76 (1.56–4.89);0.001
Hypercholesterolemia 0.50 (0.27–0.90); 0.026 0.46 (0.25–0.85); 0.014
Previous bleeding 1.06 (0.46–2.45); 0.893
vWF 221 IU/dl 2.88 (1.77–4.69);0.001 2.03 (1.24–3.32); 0.005
D-dimer 1.00 (1.00–1.00); 0.465Abbreviations as in Table 2.(HR: 2.03; 95% CI: 1.24 to 3.32; p  0.005) (Table 3). Risk
actors associated with cardiovascular death were age 75
ears and older, heart failure, current smoking habit, hyper-
holesterolemia, and high plasma vWF levels (Table 4).
Independent predictors of major bleeding were male sex
HR: 0.57; 95% CI: 0.35 to 0.95; p  0.031), renal
impairment (HR: 1.99; 95% CI: 1.08 to 3.67; p  0.028),
previous bleeding episode (HR: 4.69; 95% CI: 2.79 to 7.87;
p  0.001), and high plasma vWF levels (HR: 4.47; 95%
I: 1.86 to 10.75; p  0.001) (Table 5). Figures 1A to 1D
how Kaplan-Meier curves for each adverse event in relation
o plasma vWF levels (all log-rank tests: p  0.001).
elationship of adverse events to CHADS2 and
CHA2DS2-VASc scores. Both CHADS2 and CHA2DS2-
ASc scores were predictive of adverse cardiovascular
vents, mortality, and cardiovascular death, but not major
emorrhage. The CHADS2 score showed an HR of 1.41
(95% CI: 1.20 to 1.65; p 0.001) for adverse cardiovascular
(mainly thrombotic) events, an HR of 1.57 (95% CI: 1.31 to
1.88; p  0.001) for all-cause mortality, and an HR of 1.67
Multivariate Cox Analysis for Cardiovascular DeathTable 4 Multivariate Cox Analysis for Cardiovascular Death
Univariate Analysis
HR (95% CI); p Value
Multivariate Analysis
HR (95% CI); p Value
Age 75 yrs 5.66 (1.70–18.93); 0.005 4.74 (1.38–16.26); 0.01
Male 0.54 (0.24–1.23); 0.146
Hypertension 1.14 (0.39–3.32); 0.812
Diabetes 1.78 (0.79–4.03); 0.166
Previous stroke 1.48 (0.59–3.70); 0.405
Heart failure 3.33 (1.47–7.53); 0.004 1.62 (1.14–6.01); 0.023
Coronary artery disease 1.07 (0.40–2.86); 0.885
Renal impairment 1.41 (0.42–4.70); 0.579
Current smoking habit 3.66 (1.62–8.29); 0.002 3.72 (1.40–9.84); 0.008
Hypercholesterolemia 0.30 (0.09–0.99); 0.048 0.27 (0.08–0.93); 0.038
Previous bleeding 2.03 (0.70–5.93); 0.193
vWF 221 IU/dl 4.41 (1.90–10.23); 0.001 3.05 (1.30–7.17); 0.011
D-dimer 1.00 (0.99–1.00); 0.921
Abbreviations as in Table 2.
Cox Analysis for the Composite ofMajor Hemorrhagic EventsTable 5 C x Analysis f r he Composite ofMajor Hemorrhagic Events
Univariate Analysis
HR (95% CI); p Value
Multivariate Analysis
HR (95% CI); p Value
Age 75 yrs 1.82 (1.08–3.07); 0.025 1.51 (0.87–2.60); 0.139
Male 0.55 (0.34–0.91); 0.020 0.57 (0.35–0.95); 0.031
Hypertension 1.45 (0.72–2.94); 0.296
Diabetes 0.99 (0.57–1.72); 0.984
Previous stroke 1.14 (0.62–2.09); 0.665
Heart failure 1.22 (0.75–2.00); 0.415
Coronary artery disease 1.40 (0.80–2.46); 0.238
Renal impairment 2.71 (1.48–4.97); 0.001 1.99 (1.08–3.67); 0.028
Previous bleeding 5.72 (3.45–9.47);0.001 4.69 (2.79–7.87);0.001
vWF 221 IU/dl 3.44 (2.27–5.23);0.001 4.47 (1.86–10.75); 0.001
D-Dimer 1.00 (0.99–1.00); 0.875Abbreviations as in Table 2.
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vWF Levels in Atrial Fibrillation June 21, 2011:2496–504(95% CI: 1.24 to 2.27; p  0.001) for cardiovascular death.
he CHA2DS2-VASc score showed an HR of 1.30 (95%
I: 1.44 to 1.47; p  0.001) for adverse cardiovascular
mainly thrombotic) events, an HR of 1.31 (95% CI: 1.13 to
.51; p  0.001) for all-cause mortality, and an HR of 1.35
95% CI: 1.06 to 1.71; p  0.015) for cardiovascular death.
On multivariate analysis, both the CHADS2 score and a
igh plasma vWF level (221 IU/dl) remained significantly
ssociated with prognosis. The CHADS2 score had an HR
of 1.31 (95% CI: 1.12 to 1.54; p  0.001), and for a high
Figure 1 Kaplan-Meier Analysis for Each Adverse Event in Rela
Cardiovascular events (A), hemorrhagic events (B), all-cause mortality (C), and ca
green lines indicate vWF 221 IU/dl.plasma vWF level, the HR was 3.02 (95% CI: 1.98 to 4.58;p  0.001) for adverse cardiovascular events. For all-cause
mortality, the CHADS2 score had an HR of 1.49 (95% CI:
1.23 to 1.79; p  0.001), and a high plasma vWF level had
an HR of 2.41 (95% CI: 1.48 to 3.92; p  0.001). For
cardiovascular death, the CHADS2 score had an HR of
1.56 (95% CI: 1.14 to 2.12; p  0.005), and for a high
plasma vWF level, the HR was 3.67 (95% CI: 1.57 to 8.59;
p 0.003). The CHA2DS2-VASc score also maintained its
significance on multivariate analysis when combined with
plasma vWF levels, with the exception of cardiovascular
o vWF Levels
scular death (D). Blue lines indicate von Willebrand factor (vWF) 221 IU/dl;tion t
rdiovadeath (Table 6).
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June 21, 2011:2496–504 vWF Levels in Atrial FibrillationRelationship of major bleeding events to HAS-BLED
score. The HAS-BLED score was predictive of major
bleeding events (HR: 1.90; 95% CI: 1.53 to 2.37; p 
0.001), and both the HAS-BLED score and high plasma
vWF level remained significant after multivariate analysis.
The HAS-BLED score showed an HR of 1.80 (95% CI:
1.44 to 2.25; p  0.001), and for a high plasma vWF level,
the HR was 2.81 (95% CI: 1.71 to 4.61; p  0.001).
Additive effect of vWF on clinical risk scores. Annual-
ized event rates for the CHADS2, CHA2DS2-VASc, and
AS-BLED risk scores by plasma vWF level are shown
n Tables 6 and 7. The highest risk strata were those with
igh-risk clinical criteria plus high plasma vWF levels for
oth thrombotic and bleeding events. Those with mod-
rate risk clinical criteria plus low plasma vWF levels
ere at lower risk of an event, but not as low as those
dentified as low risk, but there was clear separation of the
nnualized event rates for moderate-risk clinical criteria
lus low plasma vWF levels versus high-risk clinical
riteria plus low plasma vWF levels according to all risk
cores.
Additive Value of vWF Levels to CHADS2 and CHA2DS2-VASc ScoreTable 6 Additive Value of vWF Levels to CHADS2 and CHA2DS2
No. (Annual Rate) vW
Thrombosis
CHADS2
Low (n  40) 1 (1.1%)
Intermediate (n  430) 36 (3.8%)
High (n  359) 58 (7.3%)
Death
CHADS2
Low (n  40) 0
Intermediate (n  430) 26 (2.7%)
High (n  359) 43 (5.4%)
Thrombosis
CHA2DS2-VASc
Low (n  9) 0
Intermediate (n  41) 1 (1.1%)
High (n  779) 94 (5.5%)
Death
CHA2DS2-VASc
Low (n  9) 0
Intermediate (n  41) 0
High (n  779) 69 (4.0%)
CHADS2: low  0, intermediate  1 to 2, high 3; CHA2DS2-VASc: low  0, intermediate  1, h
CHA2DS2-VASc  congestive heart failure, hypertension, age 75 years, diabetes mellitus, stro
Additive Role of vWF Levels to HAS-BLED Score for Hemorrhagic ETable 7 Additive Role of vWF Levels to HAS-BLED Score for He
Hemorrhage HAS-BLED No. (Annual Rate) vWF
Low (n  18) 0
Intermediate (n  534) 26 (2.2%) 10
High (n  277) 42 (6.7%) 17
HAS-BLED: low  0, intermediate  1 to 2, high 3; vWF low: 221 IU/dl; vWF high: 221 IU/d
HAS-BLED  Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, La
n Table 2.iscussion
n this study, we showed for the first time how an increased
lasma vWF level, an established marker for endothelial
amage/dysfunction, is associated with an adverse prognosis
n AF patients, with regard to cardiovascular (mainly
hrombotic) events, mortality, and bleeding. We also ap-
lied the new CHA2DS2-VASc and HAS-BLED scores
and showed that the addition of plasma vWF levels as
another biomarker risk factor would help to refine these
clinical risk stratification schemes for stroke and bleeding.
AF patients constitute a high-risk population with both
cardiovascular and hemorrhagic events. The Framingham
Heart Study demonstrated that sex, age, diabetes, hyperten-
sion, chronic heart failure, and cardiac valve disease were
independent risk factors for AF (24). Such risk factors were
also recognized risk factors for stroke and thromboembo-
lism and were included in clinical schemes designed for
recommending thromboprophylaxis, but these variables are
also established cardiovascular risk factors. Data from the
REACH (REduction of Atherothrombosis for Continued
Health) study demonstrated that CHADS2 is also a good
the Composite of Thrombosis and Mortalityc Scores for the Composite of Thrombosis and Mortality
el Low vWF Level High HR (95% CI); p Value
2%) 0 —
2%) 21 (8.0%) 3.64 (1.87–7.06);0.001
3%) 37 (12.0%) 2.66 (1.56–4.56);0.001
— —
7%) 14 (5.3%) 2.82 (1.30–6.10); 0.008
5%) 26 (8.5%) 2.27 (1.23–4.19); 0.008
— —
2%) 0 —
1%) 58 (10.3) 3.24 (2.13–4.91);0.001
— —
— —
5%) 40 (7.1%) 2.66 (1.64–4.29);0.001
vWF low: 221 IU/dl; vWF high: 221 IU/dl.
cular disease, age 65 to 74 years, sex category; other abbreviations as in Tables 1 and 2.
hagic Events
Low vWF Level High HR (95% CI); p Value
— —
) 16 (4.7%) 3.87 (1.75–8.53);0.001
) 25 (11.0%) 2.44 (1.30–4.59); 0.005s for-VAS
F Lev
1 (1.
15 (2.
21 (4.
—
12 (2.
17 (3.
—
1 (1.
36 (3.
—
—
29 (2.ventsmorr
Level
—
(1.2%
(4.4%
l.
bile International Normalized Ratio, Elderly, Drugs/alcohol concomitantly; other abbreviations as
a
A
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c
c
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vWF Levels in Atrial Fibrillation June 21, 2011:2496–504scoring system for predicting cardiovascular outcomes in
patients with and at-risk of atherothrombosis (25). During
the follow-up period in the present study, we observed a rate
of thrombotic events of 5.0% per year, including 1.7% per
year for stroke, 1.9% per year for acute coronary syndrome,
and 1.5% for acute heart failure. The incidence of stroke in
AF patients with adjusted oral anticoagulation ranges from
1.2% to 2.0% per year (26), whereas the rate of fatal and
nonfatal myocardial infarction ranges from 0.5% to 4% per
year (27).
In the present study, we found that the strongest risk
factors for thrombotic events were age 75 years and older
and high plasma vWF levels. This is not surprising in an
elderly population with AF in which, despite the use of oral
anticoagulants, the incidence of thrombotic events (includ-
ing stroke, myocardial infarction, and vascular death) was
5.9% per year (28). In our study, 57% of AF patients were
older than 75 years of age and 29% were older than 80 years
of age. Second, we had a prevalent cardiovascular risk factor
population, with 80% with hypertension, 30% with hy-
percholesterolemia, and 25% with diabetes; moreover, most
of our patients (76%) were at moderate to high risk of
thromboembolism (CHADS2 risk score 2). There is also
a high incidence of AF among patients with atherothrom-
bosis, in whom AF was associated with a major increase in
cardiovascular events, and the CHADS2 score was predic-
tive not only of stroke but also of cardiovascular death
(15,29), even in non-AF patients (25). In this setting, we
found that the CHADS2 risk score was predictive of adverse
cardiovascular events, being a composite of thrombotic
events, global mortality, and cardiovascular death.
Increased plasma vWF levels have been found in inflam-
matory and atherosclerotic vascular diseases (9). vWF may
play an important role in the pathogenesis of atherosclerosis,
being associated with subsequent cardiovascular events (30).
vWF is increased in AF patients (31), but it remains
controversial whether such an increase is due to the AF itself
or coexistent cardiovascular risk factors (32). Independent
associations between several AF stroke risk factors and vWF
have been shown (11) as well as a correlation with the
CHADS2 risk score (13). Also, plasma vWF levels were
predictive of subsequent stroke and vascular events in AF
and had an additive role to clinical factors for risk stratifi-
cation (12,33). Our study provides evidence that the plasma
vWF level consistently predicts cardiovascular events,
stroke, coronary syndrome and acute heart failure, major
bleeding events, and mortality (both cardiovascular and all
cause) in a large cohort of consecutive anticoagulated AF
patients, even after adjusting for confounding factors and of
having an additive effect on clinical risk stratification
schemes. Moreover, the plasma vWF level was also
predictive of stroke (HR: 5.04) and acute coronary
syndrome (HR: 3.42) (both p  0.001). As recently
reviewed, there is a strong correlation between elevated
plasma vWF levels and the incidence and prognosis of
acute coronary syndrome (34). oSimilar prognostic data have been reported for DD, even
in patients receiving OAC therapy (15,16), but in this study,
we were not able to find such an association. Inclusion
criteria at study entry was the time in therapeutic range
(TTR) during the previous 6 months of 100% (international
normalized ratio between 2.0 and 3.0), and, thus, the DD
values may have been suppressed so much that we did not
find any significant impact of plasma DD levels, whereas in
previously published studies, the TTR was not reported.
Bleeding events prediction deserves special attention.
High plasma vWF levels also predict major bleeding,
remaining significant after multivariate analysis. Congeni-
tally decreased plasma vWF levels, as seen in von Wille-
brand disease, are associated with high bleeding risk,
whereas high levels are associated with cardiovascular risk.
In our population, high plasma vWF levels probably identify
a population at very high risk of both thrombotic and
hemorrhagic events. Indeed, risk factors for warfarin-
associated bleeding are also indications for warfarin use in
AF patients (35).
In the pooled analysis of the first 5 trials with warfarin in
AF, the annual rate of major bleeding was 1.0% in control
patients compared with 1.3% in patients treated with
warfarin, with the main predisposing factors being the
intensity of the anticoagulant effect, patient characteristics,
concomitant use of drugs that interfere with hemostasis, and
the length of therapy (36). Our independent predictors of
hemorrhage were female sex, renal impairment, previous
hemorrhagic event, and high plasma vWF levels. On
univariate analysis, age 75 years and older was predictive of
bleeding, but it lost its significance after multivariate anal-
ysis. Our rate of major hemorrhage was 3.6% per year, and
several studies showed that elderly patients are more prone
to bleeding (37–39), with annual rates of major hemor-
rhages of 1.4% (36) to 7.2% (37). No previous study found
female sex as an independent risk factor for bleeding,
except for a slightly increased HR of 1.4 of borderline
significance (40).
Accordingly, the ACTIVE-W (Atrial Fibrillation Clopi-
dogrel Trial With Irbesartan for Prevention of Vascular
Events) showed that patients with a CHADS2 risk score of
1 had a lower major bleeding risk than patients with a
CHADS2 score of 2 (41). However, we did not find any
ssociation between the CHADS2 score and bleeding risk.
lthough a systematic review identified the following pa-
ient characteristics as risk factors for anticoagulation-
elated bleeding complications—advanced age, uncontrolled
ypertension, history of ischemic heart disease, cerebrovas-
ular disease, anemia or a history of bleeding, and the
oncomitant use of other drugs such as antiplatelet agents
42)—our study only identified a history of bleeding as an
ndependent risk factor. Renal impairment has not been
reviously reported to be a risk factor for bleeding in AF
42), except for patients undergoing coronary stenting (43).
e found that the new HAS-BLED scheme was predictive
f subsequent bleeding events, even remaining significant
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June 21, 2011:2496–504 vWF Levels in Atrial Fibrillationafter multivariate analysis of plasma vWF levels. However, a
high plasma vWF level showed an additive effect on the
HAS-BLED score, for an intermediate-risk category for
bleeding (HAS-BLED score of 1 to 2 points), so that high
plasma vWF levels changed the annual risk of a hemor-
rhagic event from 1.2% (based on clinical criteria) to 4.7%.
Study limitations. At entry, the TTR was 100%, but we do
ot have data on the TTR during follow-up, which could
ffect both thrombotic and hemorrhagic events. It is also
ncertain whether plasma vWF levels bring a new, different
hysiological factor into stroke prediction in AF patients or
imply a measure of severity of previously identified clinical
redictors. Of note, the plasma vWF level maintained its
tatistical significance after adjusting for several risk factors
or both thrombotic and hemorrhagic events.
onclusions
e report in a large cohort of anticoagulated AF patients
hat plasma vWF levels were independent predictors of
hrombotic and bleeding events and death during 2 years
of follow-up. This biomarker may potentially be used to
refine stroke and bleeding risk stratification in AF.
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